Diabetes, Lipids, and CV Risk

Purpose of Review Diabetes is often associated with diabetic dyslipidemia. Both hyperglycemia and disorders of lipid metabolism strongly contribute to development of atherosclerosis, the crucial factor of cardiovascular disease. The aim of the manuscript is to summarize possible treatment to reduce...

Full description

Saved in:
Bibliographic Details
Published inCurrent atherosclerosis reports Vol. 23; no. 3; p. 8
Main Author Škrha, Jan
Format Journal Article
LanguageEnglish
Published New York Springer US 01.03.2021
Subjects
Angiology
Cardiology
Medicine
Medicine & Public Health
Section Editor
Statin Drugs (R. Ceska
Topical Collection on Statin Drugs
Prevention
Diabetes
Atherosclerosis
Cardiovascular risk
Online AccessGet full text
ISSN1523-3804
1534-6242
1534-6242
DOI10.1007/s11883-021-00905-8

Cover

More Information
Summary:Purpose of Review Diabetes is often associated with diabetic dyslipidemia. Both hyperglycemia and disorders of lipid metabolism strongly contribute to development of atherosclerosis, the crucial factor of cardiovascular disease. The aim of the manuscript is to summarize possible treatment to reduce cardiovascular risk. Recent Findings Maximal cardiovascular risk reduction is maintained by targeting more pathologic disturbances together. While antihypertensive treatment has not changed much recently, novel PCSK9 inhibitors have significantly improved management of dyslipidemia. Similarly, modern antihyperglycemic agents (SGLT2 inhibitors and GLP-1 receptor agonists) show both significant metabolic effects and cardiovascular benefits. Summary Diabetes treatment is no longer glucocentric. Apart from glucose management, there are effective pharmacologic tools for significant reduction of cardiovascular risk.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1523-3804
1534-6242
1534-6242
DOI:10.1007/s11883-021-00905-8